The Female Hormone Panel (FHP) is a dynamic mapping of the active levels of estradiol (E2) and progesterone (P) throughout one complete monthly cycle. The panel also includes a cycle average value for free testosterone and DHEA/DHEA-S. This panel uses 11 saliva samples collected during specified time slots during a menstrual cycle. The expanded panel version includes seven additional FSH and LH measurements.


Download Provider Catalog:
provider_catalog.pdf

(right click to save)

The Female Hormone Panel: Provider Overview

FHP Overview

The FHP is used to identify menstrual cycle deficits and imbalances in progesterone, estrogen, testosterone, and DHEA/DHEA-S. This panel provides a profile of the hormone fluctuations in a woman’s cycle for test-guided BHRT. The FHP test is most applicable in cycling women with any of the following conditions:

  • Weight gain
  • Functional infertility
  • Osteoporosis
  • Endometriosis and ovarian cysts
  • Fibroids and fibrocystic breasts
  • Increased risk of breast cancer
  • Recurrent cycle-related symptoms and irregularities, such as PMS, migraines, breast tenderness, emotional and cognitive issues, insomnia and spotting

Representation of Hormone Cycle

Phases of Female Cycle

Clinical Applications

Customize BHRT

Presently hormone therapy is very empirical, and a one-size-fits-all approach is applied to most women. Due to variability among women, and the natural cyclical changes in hormones, a more frequent sampling is needed for proper hormone quantification. A single sample taken between day 20 and 22 of a cycle is less than 50% accurate. The Female Hormone Panel remedies this shortcoming by using a schedule for 11 samples distributed over a full cycle - start to end.

The FHP report includes 11 estradiol (E2) and 11 progesterone (P) measurements, cycle average DHEA/DHEA-S and testosterone, three progesterone production indices, four estradiol production indices, and a full-cycle P/E ratio graph.

Assess Risk of Breast and Uterine Distress

It is universally accepted that there is an increased risk of proliferative disease in breast and endometrial tissue when estrogen is overly dominant. The FHP basic and expanded reports both include the follicular estrogen priming index (EΠ), which quantifies the impact of excess estradiol in menstruating women.